Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 4/20/12 → 7/31/17 |
Funding
- Millennium Pharmaceuticals Inc: $349,099.00
A Multicenter, Phase 1-2 study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients with Relapsed or Refractory Aggressive B-Cell Lympohma Treated with Rituximab and Vincristine
- Monohan, Gregory (PI)
- Hayslip, John (Former PI)
- McDonagh, Kevin (Former PI)